http://orcid.org/0000-0002-8393-9691
Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Shuanzhi Wu, Tenghua Wang, Jieyun Li, Zhixin Zhang, Chen Li, Shuangshuang Xiao, Jin He, Xuan Wang, Zhiqin Hu, Xiaole Wang, Sichao Zheng, Xintong Liang, Guiying Chen, Yongmei Li, Xianbo Li, Yaoxuan Zhan, Qinwen Zou, Hongliang Jiang, Qingshan Zheng, Li Ban, Haiyan Liu & Yi Fang. (2023) First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa. Expert Opinion on Investigational Drugs 32:11, pages 1085-1094.
Read now
Read now
Antonio Gómez-Outes, M Luisa Suárez-Gea, Alejandro-Isidoro Pérez-Cabeza & Jose Manuel García-Pinilla. (2022) Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions. Expert Opinion on Pharmacotherapy 23:17, pages 1941-1955.
Read now
Read now
Rami A. Al-Horani. (2020) Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present). Expert Opinion on Therapeutic Patents 30:1, pages 39-55.
Read now
Read now
Xia Hao, Xiaofang Zuo, Dongwei Kang, Jian Zhang, Yuning Song, Xinyong Liu & Peng Zhan. (2019) Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors. Expert Opinion on Drug Discovery 14:9, pages 915-931.
Read now
Read now
Orsolya Székely, Marco Borgi & Gregory Y. H. Lip. (2019) Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation. Expert Opinion on Emerging Drugs 24:1, pages 55-61.
Read now
Read now
Orsolya Székely, Kazuo Miyazawa & Gregory Yoke Hong Lip. (2018) Current and emerging pharmacotherapy for ischemic stroke prevention in patients with atrial fibrillation. Expert Opinion on Pharmacotherapy 19:18, pages 1999-2009.
Read now
Read now
Articles from other publishers (15)
Qinqin Li, Hao Zhang, Shanshan Guan, Juan Du, Yurou Zhang & Song Wang. (2023) Molecular dynamics simulation of the inhibition mechanism of factor XIa by Milvexian-like macrocyclic inhibitors. Computational and Theoretical Chemistry 1225, pages 114131.
Crossref
Crossref
Zeyu Guan, Roxanna Wang, Rawaa H. Hussain, James C. Fredenburgh, Iqbal H. Jaffer & Jeffrey I. Weitz. (2023) Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. Journal of Thrombosis and Haemostasis 21:1, pages 76-82.
Crossref
Crossref
Omri Cohen & Walter Ageno. (2022) Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism. Hematology 2022:1, pages 495-505.
Crossref
Crossref
Tingting Ma, Yanli Dong, Lei Huang, Yuanxun Yang, Yan Geng, Fei Fei, Pinhao Xie, Yu Zhao, Hui Lin, Zeyu Yang, Yun Jin, Xitong Ju, Runbin Sun & Juan Li. (2022) SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor. Frontiers in Pharmacology 13.
Crossref
Crossref
Nayeon Kim, CheLynn Jeon, Chaeyeong Kim, Soo Ho Ryu, Wonhwa Lee & Jong-Sup Bae. (2022) Inhibition of factor Xa activity, platelet aggregation, and experimentally induced thrombosis by Sparstolonin B. Phytomedicine 99, pages 153987.
Crossref
Crossref
Ningning Yao, Zhiping Jia, Yongbin Tian, Shuzeng Hou, Xiaoxiao Yang, Jihong Han, Yajun Duan, Chenzhong Liao, Yi Kong & Zhouling Xie. (2022) Targeting the S2 Subsite Enables the Structure-Based Discovery of Novel Highly Selective Factor XIa Inhibitors. Journal of Medicinal Chemistry 65:5, pages 4318-4334.
Crossref
Crossref
Yu Lei, Bing Zhang, Yan Zhang, Xiwen Dai, Yulin Duan, Qing Mao, Jun Gao, Yuwei Yang, Ziyang Bao, Xuefeng Fu, Kunqi Ping, Chengda Yan, Yanhua Mou & Shaojie Wang. (2021) Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment. European Journal of Medicinal Chemistry 220, pages 113437.
Crossref
Crossref
Yubin Liu, Meixia Wang, Xiaona Dong, Jia He, Lin Zhang, Ying Zhou, Xia Xia, Guifang Dou, Chu‐tse Wu & Jide Jin. (2021) A phase I, single and continuous dose administration study on the safety, tolerability, and pharmacokinetics of neorudin, a novel recombinant anticoagulant protein, in healthy subjects. Pharmacology Research & Perspectives 9:3.
Crossref
Crossref
Kyung‐Min Kim, Jaehong Kim, Moon‐Chang Baek & Jong‐Sup Bae. (2020) Novel factor Xa inhibitor, maslinic acid, with antiplatelet aggregation activity. Journal of Cellular Physiology 235:12, pages 9445-9456.
Crossref
Crossref
So Yeon Jeong, Mijeong Lee, Ji Sun Lim, Eui Kyun Park, Moon-Chang Baek, Jong-Sang Kim, Dongyup Hahn & Jong-Sup Bae. (2020) Phenanthrenes isolated from diocorea batatas Decne peel with anti-platelet aggregation activity via direct factor Xa inhibitory activity. Journal of Functional Foods 73, pages 104138.
Crossref
Crossref
Nigel Mackman, Wolfgang Bergmeier, George A. Stouffer & Jeffrey I. Weitz. (2020) Therapeutic strategies for thrombosis: new targets and approaches. Nature Reviews Drug Discovery 19:5, pages 333-352.
Crossref
Crossref
Kenneth A. Bauer. (2020) How Effective and Safe Is Factor XI Inhibition in Preventing Venous Thrombosis?. JAMA 323:2, pages 121.
Crossref
Crossref
Masahiro IEKO, Kazuki KIYOHARA, Akihiro OTSU & Kenji SHIMOSEGAWA. (2020) Current status of anticoagulant therapy and development of coagulation factor XI(a) inhibitors抗凝固療法の現状と凝固第XI(a)因子阻害薬の開発状況. Japanese Journal of Thrombosis and Hemostasis 31:6, pages 619-623.
Crossref
Crossref
Suzanne Murray, Claire McLintock, Patrice Lazure, Morgan Peniuta, Sam Schulman, Suely M. Rezende, James H. Morrissey, Thomas Reiser & Ingrid Pabinger. (2019) Needs and challenges among physicians and researchers in thrombosis and hemostasis: Results from an international study. Research and Practice in Thrombosis and Haemostasis 3:4, pages 626-638.
Crossref
Crossref
Benjamin F. Tillman, Andras Gruber, Owen J.T. McCarty & David Gailani. (2018) Plasma contact factors as therapeutic targets. Blood Reviews 32:6, pages 433-448.
Crossref
Crossref